Perampanel Efficacy and Safety in Pediatric Epilepsy: A Single-Center Prospective Study

Data Sheet 1 presents results from a real-world, single-center prospective observational study on perampanel as the first antiseizure medication for children with newly diagnosed epilepsy. The study, conducted at Shenzhen Children's Hospital between August 2021 and August 2023, included 137 patients and tracked seizure-free, response, and medication retention rates at 6 and 12 months. Wenmin Huang authored this dataset, which was last updated on 2026-05-28.

Use Cases

• Analyze seizure-free and response rates over time based on the 6-month and 12-month follow-up data mentioned in the description
• Investigate adverse event profiles and medication retention based on the recorded adverse events and discontinuation rates
• Compare treatment efficacy between patient subgroups, such as those with self-limited epilepsy with centrotemporal spikes (SeLECTS), based on the subgroup analysis described
• Model factors linked to treatment efficacy based on patient characteristics like age, epilepsy history duration, and initial dosage mentioned in the results

Strengths

• Includes data on 137 pediatric patients with a detailed follow-up attrition rate of 1.5%
• Reports specific outcome metrics including a 12-month seizure-free rate of 64.1% and a response rate of 90.6% at 12 months
• Documents adverse event rates (24.8%) and common types like dizziness and drowsiness for safety assessment

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data is from a single-center study, which may limit generalizability

Provenance

Source

Shenzhen Children's Hospital

Collection Method

Single-center prospective observational study

Time Range

August 2021 to August 2023

Freshness

Last updated 2026-05-28 06:16:29; freshness should be verified

Geography

Shenzhen, China